TY - JOUR
T1 - Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy
T2 - Can they help predict risk of preterm birth?
AU - Ramsden, Christopher E.
AU - Makrides, Maria
AU - Yuan, Zhi Xin
AU - Horowitz, Mark S.
AU - Zamora, Daisy
AU - Yelland, Lisa N.
AU - Best, Karen
AU - Jensen, Jennifer
AU - Taha, Ameer Y.
AU - Gibson, Robert A.
N1 - Funding Information:
Supported by the intramural programs of the National Institute on Alcohol Abuse and Alcoholism and National Institute on Aging, National Institutes of Health, the University of Adelaide, the South Australian Health and Medical Research Institute, and USDA National Institute of Food and Agriculture, Hatch/Taha (project #1008787). The original study was supported by grants from the Australian National Health and Medical Research Council (NHMRC) (1050468) and the Thyne Reid Foundation, and fellowships awarded to M Makrides (1061704), RA Gibson (1046207) and LN Yelland (1052388) from the Australian NHMRC. Croda UK provided the oils and Wassen UK the encapsulation. Collection of the extra samples used in this study were supported by the NHMRC Centre of Research Excellence in Foods for Future Australians (1035530). We would like to acknowledge the ORIP Steering Committee for their contributions to the main trial and Beverly Muhlhausler for assistance with location and transport of samples. We would also like to acknowledge the ORIP study participants.
Funding Information:
Supported by the intramural programs of the National Institute on Alcohol Abuse and Alcoholism and National Institute on Aging , National Institutes of Health , the University of Adelaide , the South Australian Health and Medical Research Institute , and USDA National Institute of Food and Agriculture , Hatch/Taha (project #1008787). The original study was supported by grants from the Australian National Health and Medical Research Council (NHMRC) ( 1050468 ) and the Thyne Reid Foundation , and fellowships awarded to M Makrides ( 1061704 ), RA Gibson ( 1046207 ) and LN Yelland ( 1052388 ) from the Australian NHMRC. Croda UK provided the oils and Wassen UK the encapsulation. Collection of the extra samples used in this study were supported by the NHMRC Centre of Research Excellence in Foods for Future Australians ( 1035530 ). We would like to acknowledge the ORIP Steering Committee for their contributions to the main trial and Beverly Muhlhausler for assistance with location and transport of samples. We would also like to acknowledge the ORIP study participants.
PY - 2020/2
Y1 - 2020/2
N2 - Oxidized lipids derived from omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids, collectively known as oxylipins, are bioactive signaling molecules that play diverse roles in human health and disease. Supplementation with n-3 docosahexaenoic acid (DHA) during pregnancy has been reported to decrease the risk of preterm birth in singleton pregnancies, which may be due to effects of DHA supplementation on oxylipins or their precursor n-6 and n-3 fatty acids. There is only limited understanding of the levels and trajectory of changes in plasma oxylipins during pregnancy, effects of DHA supplementation on oxylipins and unesterified fatty acids, and whether and how oxylipins and their unesterified precursor fatty acids influence preterm birth. In the present study we used liquid chromatography-tandem mass spectrometry to profile oxylipins and their precursor fatty acids in the unesterified pool using plasma samples collected from a subset of pregnant Australian women who participated in the ORIP (Omega-3 fats to Reduce the Incidence of Prematurity) study. ORIP is a large randomized controlled trial testing whether daily supplementation with n-3 DHA can reduce the incidence of early preterm birth compared to control. Plasma was collected at study entry (≈pregnancy week 14) and again at ≈week 24, in a subgroup of 48 ORIP participants—12 cases with spontaneous preterm (<37 weeks) birth and 36 matched controls with spontaneous term (≥40 weeks) birth. In the combined preterm and term pregnancies, we observed that in the control group without DHA supplementation unesterified AA and AA-derived oxylipins 12-HETE, 15-HETE and TXB2 declined between weeks 14–24 of pregnancy. Compared to control, DHA supplementation increased unesterified DHA, EPA, and AA, DHA-derived 4-HDHA, 10-HDHA and 19,20-EpDPA, and AA-derived 12-HETE at 24 weeks. In exploratory analysis independent of DHA supplementation, participants with concentrations above the median for 5-lipoxygenase derivatives of AA (5-HETE, Odds Ratio (OR) 8.2; p = 0.014) or DHA (4-HDHA, OR 8.0; p = 0.015) at 14 weeks, or unesterified AA (OR 5.1; p = 0.038) at 24 weeks had higher risk of spontaneous preterm birth. The hypothesis that 5-lipoxygenase-derived oxylipins and unesterified AA could serve as mechanism-based biomarkers predicting spontaneous preterm birth should be evaluated in larger, adequately powered studies.
AB - Oxidized lipids derived from omega-6 (n-6) and omega-3 (n-3) polyunsaturated fatty acids, collectively known as oxylipins, are bioactive signaling molecules that play diverse roles in human health and disease. Supplementation with n-3 docosahexaenoic acid (DHA) during pregnancy has been reported to decrease the risk of preterm birth in singleton pregnancies, which may be due to effects of DHA supplementation on oxylipins or their precursor n-6 and n-3 fatty acids. There is only limited understanding of the levels and trajectory of changes in plasma oxylipins during pregnancy, effects of DHA supplementation on oxylipins and unesterified fatty acids, and whether and how oxylipins and their unesterified precursor fatty acids influence preterm birth. In the present study we used liquid chromatography-tandem mass spectrometry to profile oxylipins and their precursor fatty acids in the unesterified pool using plasma samples collected from a subset of pregnant Australian women who participated in the ORIP (Omega-3 fats to Reduce the Incidence of Prematurity) study. ORIP is a large randomized controlled trial testing whether daily supplementation with n-3 DHA can reduce the incidence of early preterm birth compared to control. Plasma was collected at study entry (≈pregnancy week 14) and again at ≈week 24, in a subgroup of 48 ORIP participants—12 cases with spontaneous preterm (<37 weeks) birth and 36 matched controls with spontaneous term (≥40 weeks) birth. In the combined preterm and term pregnancies, we observed that in the control group without DHA supplementation unesterified AA and AA-derived oxylipins 12-HETE, 15-HETE and TXB2 declined between weeks 14–24 of pregnancy. Compared to control, DHA supplementation increased unesterified DHA, EPA, and AA, DHA-derived 4-HDHA, 10-HDHA and 19,20-EpDPA, and AA-derived 12-HETE at 24 weeks. In exploratory analysis independent of DHA supplementation, participants with concentrations above the median for 5-lipoxygenase derivatives of AA (5-HETE, Odds Ratio (OR) 8.2; p = 0.014) or DHA (4-HDHA, OR 8.0; p = 0.015) at 14 weeks, or unesterified AA (OR 5.1; p = 0.038) at 24 weeks had higher risk of spontaneous preterm birth. The hypothesis that 5-lipoxygenase-derived oxylipins and unesterified AA could serve as mechanism-based biomarkers predicting spontaneous preterm birth should be evaluated in larger, adequately powered studies.
KW - Arachidonic
KW - Development
KW - Docosahexaenoic
KW - Linoleic
KW - Oxylipins
KW - Plasma
KW - Preterm
UR - http://www.scopus.com/inward/record.url?scp=85077661061&partnerID=8YFLogxK
U2 - 10.1016/j.plefa.2019.102041
DO - 10.1016/j.plefa.2019.102041
M3 - Article
C2 - 31931275
AN - SCOPUS:85077661061
SN - 0952-3278
VL - 153
JO - Prostaglandins Leukotrienes and Essential Fatty Acids
JF - Prostaglandins Leukotrienes and Essential Fatty Acids
M1 - 102041
ER -